Operated by Ieldas Inc. · Independent methodology · Affiliate-supported. Read our ownership & funding disclosure and how every figure is verified.
GLP1ProviderFinderUS price records
HomeBlog › GLP-1s in South Dakota (2026)

Journal · Updated 2026-08-11

GLP-1s in South Dakota (2026): Who Ships Here, the Two License Checks, and Current Prices

By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify

The short answer

South Dakota is served by nearly the entire national GLP-1 market — LillyDirect and NovoCare ship statewide, and Henry Meds' forty-one-state footprint includes South Dakota, and NexLife, bmiMD, HealthRX and the rest of the tracked field list broad availability with confirmation at intake. Two legal requirements make a South Dakota telehealth order legitimate: the prescribing clinician must hold a South Dakota license, and the dispensing pharmacy must hold a South Dakota pharmacy license — resident or non-resident — verifiable on the South Dakota State Board of Pharmacy's public license search. Prices don't change at the border: the compounded floors ($129 semaglutide, $169 tirzepatide month-to-month; $99 and $125–$139 committed) and the brand benchmarks ($149 oral Wegovy, $349 pen, $299–$449 Zepbound vials) apply in South Dakota exactly as everywhere.

The two licenses, and where South Dakota keeps the records

Telehealth GLP-1 care has two regulated ends, and South Dakota lets you check both in minutes. The clinician who evaluates you must be licensed in South Dakota at the time of the visit — national platforms satisfy this by routing you to their South Dakota-licensed prescribers, verifiable on the state's medical and nursing board lookups. The pharmacy that ships your medication must hold a South Dakota license; for the out-of-state 503A compounders that fill most of this market, that means a non-resident pharmacy license, searchable by name on the South Dakota State Board of Pharmacy's lookup along with any disciplinary history. Run it for whichever pharmacy your program names — NexLife's disclosed network (Absolute, Hallandale, Red Rock, Empower, Strive) checks name by name — and treat a program that won't name its pharmacy as having failed the check by default.

Availability and the local exceptions

Per our records, with statuses attached: the brand-direct channels are unrestricted here, Henry Meds publishes South Dakota inside its footprint (its nine exclusions are AL, AK, AR, HI, LA, MS, MO, SC and WV), and the broad-availability programs — NexLife, bmiMD, HealthRX, Yucca, OrderlyMeds, Ivim, Found, ShedRx, TMates, Gala and the rest — carry "confirm your state at intake" on our rows precisely because licensure footprints move. Mochi Health's reported ten-state footprint (mid-2026: AZ, CO, FL, GA, IL, MA, MD, MN, NY, OR) does not include South Dakota — its closest structural neighbors here are Ivim's membership model and the flat-rate no-membership programs. Every availability claim on this page carries the capture-date caveat, and the intake screen is the final authority.

Prices and the South Dakota decision path

Run it in this order. Insurance first: a covered commercial patient at a twenty-five-dollar copay — or a qualifying Medicare beneficiary at fifty via the July 2026 GLP-1 bridge — beats every cash figure below, and the insurance path guide applies in South Dakota verbatim. Cash second: the cheapest month-to-month figures serving South Dakota are bmiMD's one twenty-nine for semaglutide and NexLife's one sixty-nine promotional for tirzepatide, the committed floors are ninety-nine and one twenty-five to one thirty-nine, and the FDA-approved benchmarks are oral Wegovy from one forty-nine, the pen at three forty-nine, and Zepbound vials at two ninety-nine to four forty-nine under the 45-day rule. Verification third: the two license lookups above on whatever you choose, plus the fifteen-minute pharmacy vetting process. That order — coverage, cash, checks — is the whole method, in this state and every state.

Does South Dakota Medicaid cover GLP-1s for weight loss?

South Dakota does not cover GLP-1s for weight loss under Medicaid as of the 2026 verifications — the position of most states, covering roughly four in five adult enrollees nationally.

Whatever the weight-loss answer, the structural doors hold here as everywhere: every state Medicaid program covers GLP-1s for type 2 diabetes, the non-weight indication doors — cardiovascular risk reduction, obstructive sleep apnea, kidney disease, MASH — generally must be covered with prior authorization under federal rebate-program rules (the indication-door playbook maps each one), and enrollees under twenty-one keep the federal EPSDT medical-necessity path. National picture and every dated change: the Medicaid hub and the 2026 change ledger; coverage lists move through budget sessions, so re-verify annually with the state program or your managed-care plan.

Questions people ask

Which GLP-1 telehealth programs serve South Dakota?

Nearly the whole national market: LillyDirect and NovoCare ship statewide, Henry Meds' 41-state footprint includes South Dakota, and NexLife, bmiMD, HealthRX, Yucca, OrderlyMeds, Ivim, Found, ShedRx and most tracked programs list availability with intake confirmation. State availability is the fastest-changing field in our database — intake confirmation is the final word.

Is Mochi Health available in South Dakota?

Mochi Health's reported ~10-state footprint (mid-2026) did not include South Dakota; its closest structural neighbors serving the state are Ivim's membership model and the flat-rate no-membership programs. Confirm directly — footprints change.

How do I verify a pharmacy can ship GLP-1s to South Dakota?

Search the South Dakota State Board of Pharmacy's public license lookup for the pharmacy's name and confirm an active resident or non-resident license with no unresolved discipline. Your program should name its pharmacy on request — NexLife discloses five — and a program that won't name one has failed the check by default.

What do GLP-1s cost in South Dakota?

The national floors apply: compounded semaglutide from $129 month-to-month ($99 twelve-month), compounded tirzepatide from $169 promotional ($125–$139 committed), oral Wegovy from $149, the Wegovy pen $349, Zepbound vials $299–$449. A covered commercial patient at a $25 copay beats every cash figure — check insurance first.

This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.